Peter J. Armenio

• Lead counsel for a research foundation in a confidential collaboration agreement arbitration against a specialty pharmaceutical company, obtaining specific performance and other requested relief (JAMS Arbitration) (March 2024)*
• Lead outside IP counsel for Karuna Therapeutics, Inc. in the announced $14 billion sale of the company to Bristol Myers Squibb (December 2023)*
• Lead counsel for LumiThera, formerly MacuLogix, in patent infringement litigation brought to protect its AdaptDx® and AdaptDX Pro® ophthalmic devices for measuring dark adaptation, obtaining a favorable settlement (D. Del. and PTAB) (August 2022)*
• Lead counsel for BlephEx in patent infringement litigation regarding its ophthalmic instruments, obtaining a Federal Circuit decision confirming its free speech right to discuss infringement of its patents (Fed. Cir.) (April 2020)*, a preliminary injunction against that infringement (E.D. Mich.) (Oct. 2020)*, an appellate affirmance of that injunction (Fed. Cir.) (Feb. 2022)*, and a consent judgment with a permanent injunction (E.D. Mich.) (May 2022)*
• Represented Janssen Pharmaceuticals and Mitsubishi Tanabe in Hatch-Waxman patent infringement litigation brought to protect their INVOKANA® and INVOKAMET® brand crystalline canagliflozin products for the treatment of type 2 diabetes, obtaining a consent judgment with an injunction against the sole remaining defendant on the eve of trial (D.N.J.) (July 2021)*
• Lead counsel for a physician inventor in a confidential patent license agreement arbitration against an international medical equipment manufacturer, obtaining an eight-figure damages award (JAMS Arbitration) (June 2021)*
• Lead counsel for a venture philanthropy foundation in a confidential mRNA development agreement arbitration against an international pharmaceutical company, obtaining an eight-figure damages award (ICDR Arbitration) (Nov. 2020)*
• Lead counsel for Allergan in Hatch-Waxman patent infringement litigation brought to protect its LINZESS® brand linaclotide peptide products for the treatment of IBS-C, obtaining consent judgments with injunctions against all defendants (D. Del.) (Jan. 2020)*
• Lead counsel for Pfizer and Merck KGaA in patent infringement litigation brought against their BAVENCIO® brand anti-PD-L1 antibodies for the treatment of various cancers, and related patent inventorship litigation, obtaining a dismissal of all claims, with prejudice (D. Del. and D. Mass.) (Feb. 2019)*
• Lead counsel for inAuth, a subsidiary of American Express, in patent infringement litigation brought against its authentication services, obtaining a consent order dismissing all claims, with prejudice (C.D. Cal.) (Jan. 2019)*
• Lead counsel for Neos Therapeutics in Hatch-Waxman patent infringement litigation brought to protect its COTEMPLA XR-ODT® brand extended-release orally disintegrating methylphenidate products for the treatment of ADHD, obtaining a consent judgment with an injunction (D. Del.) (Dec. 2018)*
• Lead counsel for Neos Therapeutics in Hatch-Waxman patent infringement litigation brought to protect its ADZENYS XR-ODT® brand extended-release orally disintegrating amphetamine products for the treatment of ADHD, obtaining a consent judgment with an injunction (D. Del.) (Oct. 2017)*
• Lead counsel for Myriad Genetics in patent infringement litigation brought against its myRISK® brand tests for genetic mutations associated with an increased risk for cancer, obtaining a dismissal of all claims (M.D.N.C.) (Aug. 2017)*
• Lead counsel for Ion Torrent, a subsidiary of Thermo Fisher Scientific, in patent infringement litigation brought against its DNA sequencing systems and consumables, obtaining a dismissal of all claims, with prejudice (D. Del.) (Apr. 2017)*
• Lead counsel for AngioScore, a subsidiary of Spectranetics, in patent inventorship litigation brought against key patents covering its ANGIOSCULPT® scoring balloon catheters, obtaining a dismissal of all claims, with prejudice (N.D. Cal.) (Mar. 2017)*
• Lead counsel for Allergan and Takeda in Hatch-Waxman patent infringement litigation brought to protect their TEFLARO® brand ceftaroline products for the treatment of drug-resistant bacterial infections, obtaining a consent judgment with an injunction against the sole remaining defendant (D. Del.) (Jan. 2017)*
• Lead counsel for Allergan in Hatch-Waxman patent infringement litigation brought to protect its NAMZARIC® brand combination donepezil and extended-release memantine products for the treatment of Alzheimer's disease, obtaining consent judgments with injunctions against all defendants (D. Del.) (Sept. 2016)*
• Lead counsel for Life Technologies, a subsidiary of Thermo Fisher Scientific, in patent infringement litigation brought against its DNA sequencing systems and consumables, obtaining a dismissal of all claims, with prejudice (M.D.N.C.) (Sept. 2015)*
• Lead counsel for Mallinckrodt in breach of contract litigation brought against its commercialization of the PENNSAID® brand topical NSAID products, obtaining a stipulated dismissal of all claims, with prejudice (S.D.N.Y.)*
• Lead counsel for AMEX in patent infringement litigation brought against its prepaid cards, obtaining summary judgment of non-infringement and invalidity (W.D. Wis.)* 
• Lead counsel for Meda Pharmaceuticals in Hatch-Waxman patent infringement litigation brought to protect its ASTEPRO® brand anti-allergy nasal spray, obtaining consent judgments with injunctions against multiple defendants (D.N.J.)*
• Lead counsel for Covidien in patent infringement litigation brought against its VERSAPORT™ PLUS surgical trocar products, obtaining summary judgment of non-infringement (C.D. Cal.)*
• Lead counsel for AMEX in patent infringement litigation brought against its Travelers Cheque™ Card products, obtaining summary judgment of non-infringement and a Federal Circuit affirmance (D. Conn. and Fed. Cir.)*
• Lead counsel for Meda Pharmaceuticals in a senior executive employment arbitration, obtaining a Panel judgment in favor of Meda on all counts (AAA arbitration)*
• Lead counsel for AMEX in patent infringement litigation brought against its contactless ExpressPay™ products, obtaining a consent judgment of non-infringement after a dispositive Markman hearing and a Federal Circuit affirmance (C.D. Cal. and Fed. Cir.)*
• Lead counsel for H. Lundbeck A/S and Forest Laboratories in patent infringement litigation brought against the manufacture of their LEXAPRO® and CELEXA® brand antidepressants, obtaining judgment as a matter of law and a Federal Circuit affirmance (S.D.N.Y. and Fed. Cir.)*
• Lead counsel for AMEX in patent infringement litigation brought against its prepaid card products, obtaining summary judgment of non-infringement and a Federal Circuit affirmance (W.D. Wis. and Fed. Cir.)*
• Lead counsel for Tyco Healthcare in patent infringement litigation brought to enforce its surgical trocar patents, obtaining a jury verdict of infringement and damages (E.D. Texas)*
• Lead counsel for Schering-Plough in multiple Hatch-Waxman patent infringement litigations regarding its CLARINEX® brand antihistamines, obtaining consent judgments with injunctions against all defendants (D.N.J.)*
• Lead counsel for GlaxoSmithKline in a breach of contract litigation brought against its performance under a settlement agreement regarding LAMICTAL®, obtaining judgment for GlaxoSmithKline on the pleadings (D.N.J.)*
• Lead counsel for American Express in patent infringement litigation brought against its gift card products, obtaining final judgment in favor of American Express at the Markman hearing and a Federal Circuit affirmance (M.D. Fla. and Fed. Cir.)*
• Lead counsel for Boston Scientific in an international patent infringement arbitration brought against its LIBERTE® and TAXUS LIBERTE® brand cardiovascular stents, obtaining a Tribunal judgment of non-infringement (WIPO arbitration)*
• Lead counsel for Tyco Healthcare Group in patent infringement litigation brought against its STEP™ and other surgical trocar products, obtaining a dismissal of all claims with prejudice in three actions after a combined Markman hearing (E.D. Texas)*
• Lead counsel for Meda Pharmaceuticals in multiple Hatch-Waxman patent infringement litigations brought to protect its ASTELIN® brand anti-allergy nasal spray, obtaining consent judgments with injunctions against all defendants (D. Del.)*
• Lead counsel for Cadbury Adams in patent, trademark, and trade dress infringement litigation brought against its TRIDENT®, DENTYNE®, and STRIDE® brand chewing gums, obtaining a dismissal of all claims, with prejudice (N.D. Ill.)*
• Lead counsel for Boston Scientific in patent infringement litigation brought against its EXPRESS® and TAXUS EXPRESS® brand cardiovascular stents, obtaining summary judgment of non-infringement (D. Del.)*

*Matter handled prior to joining Cahill.